Table 5. The association of CAP2 expression and the survival in cancer patients.

Cancer type	N	COX P-VALUE	HR	ENDPOINT	DATASET	PROBE ID
Blood
	34	9.83 E–3	0.21	Overall survival	GSE8970	212551_at
	158	6.49 E–3	0.2	Overall survival	GSE4475	212554_at
Brain
	67	4.07 E–2	0.31	Overall survival	GSE16581	HG-U133_plus_2
Breast
	159	8.04 E–3	0.57	Disease specific survival	GSE1456-GPL96	212554_at
	159	1.13 E–2	0.55	Relapse free survival	GSE1456-GPL96	212551_at
	159	4.23E–2	0.57	Disease specific survival	GSE1456-GPL96	212551_at
	159	1.93 E–2	0.64	Relapse free survival	GSE1456-GPL96	212554_at
Colorectal
	177	4.82 E–2	1.43	Overall survival	GSE17536	212551_at
	177	8.16 E–3	1.47	Disease specific survival	GSE17536	212554_at
	177	1.38 E–2	1.59	Disease specific survival	GSE17536	212551_at
	177	3.08 E–2	1.35	Overall survival	GSE17536	212554_at
	145	1.92 E–2	1.73	Relapse free survival	GSE17536	212554_at
	226	3.21 E–3	1.74	Disease free survival	GSE14333	212554_at
	55	3.61 E–2	1.82	Overall survival	GSE17537	212554_at
	55	3.86 E–2	1.98	Disease free survival	GSE17537	212554_at
	49	4.64 E–2	1.98	Disease specific survival	GSE17537	212554_at
lung
	104	1.46 E–2	0.47	Overall survival	Jacob-00182-MSK	212554_at
	104	6.15 E–3	0.16	Overall survival	Jacob-00182-MSK	212554_at
	117	3.69 E–2	1.43	Overall survival	GSE13213	A23P421664
	204	4.64 E–4	0.4	Relapse free survival	GSE31210	212554_at
	204	1.39 E–2	0.55	Relapse free survival	GSE31210	212551_at
Ovarian
	278	1.21E–2	1.38	Overall survival	GSE9891	212554_at
Prostate
	281	4.58E–2	0.82	Overall survival	GSE16560	DAP4_2808
Skin
	38	2.15E–2	1.90	Overall survival	GSE19234	212554_at
	38	3.32E–2	1.66	Overall survival	GSE19234	212554_at